Two Sigma Advisers’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-605,300
| Closed | -$22.8M | – | 2824 |
|
|
2021
Q1 | $22.8M | Buy |
605,300
+12,400
| +2% | +$309K | 0.06% | 329 |
|
|
2020
Q4 | $10.1M | Buy |
592,900
+160,200
| +37% | +$2.01M | 0.03% | 562 |
|
|
2020
Q3 | $2.03M | Buy |
432,700
+25,200
| +6% | +$128K | 0.01% | 1156 |
|
|
2020
Q2 | $2.49M | Sell |
407,500
-8,900
| -2% | -$36.7K | 0.01% | 1097 |
|
|
2020
Q1 | $945K | Buy |
416,400
+53,000
| +15% | +$225K | ﹤0.01% | 1519 |
|
|
2019
Q4 | $1.67M | Buy |
363,400
+162,800
| +81% | +$645K | ﹤0.01% | 1316 |
|
|
2019
Q3 | $777K | Buy |
200,600
+14,300
| +8% | +$78.5K | ﹤0.01% | 1544 |
|
|
2019
Q2 | $1.12M | Buy |
186,300
+34,200
| +22% | +$327K | ﹤0.01% | 1459 |
|
|
2019
Q1 | $2.04M | Sell |
152,100
-34,000
| -18% | -$388K | 0.01% | 1217 |
|
|
2018
Q4 | $1.73M | Sell |
186,100
-29,400
| -14% | -$350K | ﹤0.01% | 1239 |
|
|
2018
Q3 | $3M | Buy |
215,500
+34,600
| +19% | +$515K | 0.01% | 1034 |
|
|
2018
Q2 | $2.86M | Sell |
180,900
-15,000
| -8% | -$262K | 0.01% | 1131 |
|
|
2018
Q1 | $3.37M | Buy |
195,900
+132,300
| +208% | +$2.58M | 0.01% | 1011 |
|
|
2017
Q4 | $1.39M | Buy |
63,600
+56,100
| +748% | +$1.8M | ﹤0.01% | 1405 |
|
|
2017
Q3 | $307K | Sell |
7,500
-200
| -3% | -$6.28K | ﹤0.01% | 1923 |
|
|
2017
Q2 | $232K | Sell |
7,700
-4,700
| -38% | -$147K | ﹤0.01% | 2077 |
|
|
2017
Q1 | $448K | Buy |
12,400
+700
| +6% | +$30.9K | ﹤0.01% | 1944 |
|
|
2016
Q4 | $586K | Sell |
11,700
-33,700
| -74% | -$1.77M | ﹤0.01% | 1787 |
|
|
2016
Q3 | $2.38M | Buy |
45,400
+38,400
| +549% | +$1.83M | 0.01% | 960 |
|
|
2016
Q2 | $289K | Sell |
7,000
-14,900
| -68% | -$648K | ﹤0.01% | 1731 |
|
|
2016
Q1 | $890K | Buy |
+21,900
| New | +$753K | 0.01% | 1173 |
|
|
2015
Q3 | – | Sell |
-8,600
| Closed | -$214K | – | 2060 |
|
|
2015
Q2 | $214K | Sell |
8,600
-5,500
| -39% | -$123K | ﹤0.01% | 1731 |
|
|
2015
Q1 | $322K | Buy |
+14,100
| New | +$356K | ﹤0.01% | 1549 |
|
Two Sigma Advisers's FPRX Position: Q2 2021 in Review
Two Sigma Advisers sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 605,300 shares — an estimated $22.8M sold.
Two Sigma Advisers first reported a position in FPRX in Q1 2015 and held it in 23 quarters. The position peaked at $22.8M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Two Sigma Advisers reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Two Sigma Advisers sold 605,300 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $22.8M.
- Two Sigma Advisers first reported a position in Five Prime Therapeutics, Inc. in Q1 2015 and held it in 23 quarters.
- Two Sigma Advisers's Five Prime Therapeutics, Inc. position peaked at $22.8M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Two Sigma Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.